Meeting
2022 ASCO Annual Meeting
Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Authors
Jie Wang
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jie Wang , Zhijie Wang , Lin Wu , Baolan Li , Ying Cheng , Xiaoling Li , Xicheng Wang , Liang Han , Xiaohong Wu , Yun Fan , Yan Yu , Dongqing Lv , Jianhua Shi , Jianjin Huang , Shaozhang Zhou , Baohui Han , Guogui Sun , Qisen Guo , Youxin Ji , Xiaoli Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03856411
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9028)
DOI
10.1200/JCO.2022.40.16_suppl.9028
Abstract #
9028
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
First Author: Hai-Qiang Mai
Poster
2022 ASCO Annual Meeting
Association of progression-free survival and overall response rate with overall survival in first-line randomized trials of immune checkpoint inhibitor–based regimens for metastatic non–small cell lung cancer (NSCLC): An FDA pooled analysis.
First Author: Bernardo Haddock Lobo Goulart
Poster
2022 ASCO Annual Meeting
A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).
First Author: Caicun Zhou
Poster
2024 ASCO Genitourinary Cancers Symposium
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
First Author: Shilpa Gupta